Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fraxiketone as medicine for treating liver disease

A technology for the treatment of drugs and ketones, applied in the pharmaceutical field, can solve the problems of little research and so on

Inactive Publication Date: 2006-01-25
徐强
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Since the chemical structure of Fraxinellone was reported, there has been little research on this compound, and there have been no reports on its pharmacological activities, especially the liver-protecting and enzyme-reducing effects, and the anti-hepatic fibrosis effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fraxiketone as medicine for treating liver disease
  • Application of fraxiketone as medicine for treating liver disease
  • Application of fraxiketone as medicine for treating liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0038] 1. Isolate alkone from the root bark of Dictamnus dasycorpus Turcz., a Rutaceae plant. That is, 9.0 kg of white fresh bark coarse powder was taken, extracted with ethanol, petroleum ether, and chromatographically eluted to obtain 3.5 g of alkone. Ashone can also be isolated from other plants or obtained by chemical synthesis.

[0039] 2. To CCl 4 Induced acute liver injury in mice, oral administration of alkone 10mg / kg can significantly reduce the increase in AST activity caused by liver injury, and alkone 20 and 40mg / kg can significantly inhibit ALT and AST activity, and the effect is dose-dependent .

[0040] 3. For liver damage induced by D-GalN and LPS, asperone 10 and 20 mg / kg can significantly reduce the elevated AST activity, and has a tendency to inhibit the increase of ALT activity. Ashone 40mg / kg can significantly reduce the activity of elevated ALT and AST, and three dose groups of ashketone can improve the mortality of mice with liver injury.

[0041] 4....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of Fraxinellone as medicament for treating hepatic diseases, wherein the Fraxinellone is separated from the velamen of Dictamnus dasycorpus Turcz, the Fraxinellone can substantially improve acute hepatic injury in mouse induced with CCl4, D-galactosamine and lipopolysaccharide, in addition, the Fraxinellone can substantially inhibit the release of glutamate-pyruvate transaminase in CCl4 induced mouse primary culture hepatocytes injuries, thus can be used as a novel medicament for treating hepatic diseases.

Description

1. Technical field [0001] The invention belongs to the technical field of pharmacy. 2. Background technology [0002] Since the chemical structure of Fraxinellone was reported, there have been few studies on this compound, and there have been no reports about its pharmacological activities, especially the effects of protecting the liver, reducing enzymes, and anti-fibrosis of the liver. The present invention mainly finds that arketone can significantly improve various acute and chronic liver injuries. 3. Contents of the invention [0003] The purpose of the present invention is to study the effect of alkone in the treatment of various acute and chronic viral hepatitis, chemical hepatitis, alcoholic hepatitis, drug-induced hepatitis, severe hepatitis, fulminant liver failure, fatty liver, liver fibrosis, liver cirrhosis and other liver diseases. application in related diseases. [0004] Technical scheme of the present invention [0005] 1. Extraction, separation and stru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D307/83A61K31/365A61P1/16A61P31/14
Inventor 徐强吴斐华朱丹妮陈婷
Owner 徐强
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com